-
Ovechkin nets 1,000th combined NHL season-playoffs goal
-
Undav doubles up as Stuttgart down Augsburg to go third
-
Leftists win mayoral elections in Paris and Marseille: projections
-
Hodgkinson storms to world indoor 800m gold
-
Guardiola revels in Man City's 'special' League Cup win over Arsenal
-
Hodgkinson headlines Britain's 'Super Sunday' at world indoors
-
Messi scores for Miami in 3-2 MLS victory at NYCFC
-
Bezzecchi wins second race of the season at Brazil MotoGP
-
Britain's Hodgkinson wins world indoor 800m gold
-
Former France and West Ham star Payet announces retirement
-
Man City's O'Reilly savours 'unbelievable' double in League Cup final win
-
Slovenia liberals take narrow election lead over conservatives: exit poll
-
Man City win League Cup as O'Reilly sinks Arsenal after Kepa blunder
-
Marseille downed by Lille in Ligue 1 as Lyon's struggles continue
-
NBA bans Mitchell, Champagnie one game for sparking melee
-
'Project Hail Mary' rockets to top of N. America box office
-
Syrians protest alcohol sale limits, curbs on personal freedom
-
Spurs can '100 percent' avoid nightmare of relegation: Saltor
-
Israel launches strikes as Lebanon warns of invasion
-
Torrential rains in Kenya kill 81 in March: officials
-
Iran threatens Mideast infrastructure after Trump ultimatum
-
Spurs felled by Forest in relegation battle, Sunderland shock Newcastle
-
Spurs collapse against Forest, failing acid test
-
US may 'escalate to de-escalate' against Iran: Treasury chief
-
Howe disappointed in himself after 'painful' Newcastle defeat
-
Quansah to miss England's pre-World Cup friendlies
-
Araujo header scrapes Liga leaders Barca win over Rayo
-
Georgia buries Patriarch Ilia II as succession stirs fears of Russian influence
-
DeChambeau wins back-to-back LIV Golf play-offs
-
Sunderland inflict more derby pain on Newcastle
-
Nepali youth demand release of govt report into deadly September uprising
-
Paris doubles up with super-G victory at World Cup finals
-
Dortmund part ways with sporting director Kehl
-
Belgium remembers Brussels jihadist attacks 10 years on
-
Russia resumes use of space launch site damaged in accident
-
Cuba scrambles to restore power after new blackout
-
Senegal's Idrissa Gueye ready to 'hand back' AFCON medals
-
New Zealand's Walsh bags fourth world indoor gold
-
Goggia claims first super-G title after victory in Kvitfjell
-
Slovenia votes in tight polls, with conservatives eyeing comeback
-
A herd stop: Train kills 3 rare bison in Poland
-
Vietnam, Russia to sign energy deal: Hanoi
-
American Gumberg triumphs in Hainan for second DP World Tour win
-
South Africa clinch 19-run win over New Zealand in fourth T20
-
Iran threatens Middle East infrastructure after Trump ultimatum
-
French elect mayors in key cities including Paris
-
'They beat us with whips': Sudan RSF detainees tell of horrors in El-Fasher
-
Australia's Hannah Green wins historic third tournament in a row
-
China's premier vows to expand global 'trade pie': state media
-
Belgium commemorates Brussels attacks 10 years on
Bayer sets aside more cash to deal with weedkiller woes
German pharmaceutical and agricultural chemicals giant Bayer said it had put aside an extra 1.2 billion euros ($1.4 billion) to deal with long-running US legal woes linked to a weedkiller.
It takes to 1.7 billion euros the amount set aside to deal with litigation linked to the glyphosate-based Roundup weedkiller, the German group said in a statement late Thursday.
Bayer also said it had achieved a "major settlement" with a law firm "reducing the total number of unresolved glyphosate claims to 61,000".
This means that a total of 131,000 claims had so far either been settled or deemed not eligible, it said.
The flood of legal cases in the United States relates to claims that the weedkiller causes blood cancer. Bayer says scientific studies and regulatory approvals show that the weedkiller is safe.
The Leverkusen-based group has already spent over $10 billion to settle cases.
Despite the extra provision for the legal cases, Bayer hiked its forecasts for 2025 due to a better-than-expected performance in its pharmaceuticals division.
The maker of Aspirin now expects sales of 46 to 48 billion euros this year up from a previous forecast of 45 to 47 billion.
It also predicted earnings before interest, taxes, depreciation and amortisation -- a key measure of profitability -- of 9.7 to 10.2 billion euros up from a previous forecast of 9.5 to 10 billion.
Its shares were up two percent on the blue-chip DAX index in Frankfurt Friday, while the broader index slipped 1.8 percent.
C.Kreuzer--VB